Introduction
Telomerase, a ribonucleoprotein complex that synthesizes telomeric repeats onto chromosomal ends, is inactivated in most somatic cells and reactivated with the attainment of immortality to compensate for progressive telomere shortening caused by loss of 3' overhang on leading strand DNA synthesis to be completed all the way to the telomere end (endreplication problem) (Lingner et al., 1995) . Thus, telomerase or another mechanism to maintain telomere is necessary for the continued proliferation of cells and may be a critical and rate limiting step in cancer progression. Using a PCR-based telomerase assay called TRAP (Telomeric Repeat Ampli®cation Protocol) (Kim et al., 1994) telomerase activity has been found in approximately 85% of the most common cancers such as breast, prostate, lung, liver, pancreatic, and colon cancers (Kim, 1997; Shay and Bacchetti, 1997) , indicating that telomerase detection may be a useful marker in cancer diagnosis.
There are a vast number of proposed molecular markers for common cancers (e.g. lung, breast, and colon), but there are few commonly applicable markers. Among more than 100 proposed cancer markers, telomerase is unique as it is detected in almost all kinds of cancer tissues with a very high positive rate. In some instances, when telomerase activity appears in most tumor cells at the preneoplastic or in situ stage, telomerase activity may be useful for early detection of cancer, especially in cytology samples. In other instances, in which the level of telomerase activity is not high but increases with cancer progression (Shay and Bacchetti, 1997) , telomerase activity levels in tumor tissues may be prognostic indicators of patient outcome. Thus, at the present time telomerase is being studied in anticipation of clinical usage. In fact, several clinical trials of telomerase assay for cancer diagnosis are now in progress . The present article reviews the clinical usage of telomerase in cancer diagnosis and discusses the advantages and the problems of these markers for cancer diagnosis.
Advantages and disadvantages of the strategies being used for detecting telomerase expression in clinical materials
The most widely used strategy for detecting telomerase activity is the TRAP assay. By this method, telomerase activity can be detected in as few as 10 immortal cancer cells Wright et al., 1995) . However, telomerase activity is also detected in some kinds of normal cells, especially in proliferative stem cells and activated lymphocytes (Hiyama et al., 1995c (Hiyama et al., , 1996b Wright et al., 1996) and this can complicate the interpretation of the TRAP results. In addition, some benign tumors such as ®broadenomas of the breast (Hiyama et al., 1996a) , hyperplastic nodule/adenomas of the thyroid (Matthews et al., 2001 ) and colon adenomas (Hiyama et al., 1996b ) also have detectable telomerase activity. Since the activity levels in these benign tumors are low, quantitative analysis of telomerase activity is necessary to distinguish the upregulation of telomerase in cancer cells. The strategy for telomerase detection (TRAP assay) is based on PCR so that evaluation of its activity level can be problematic. Initially, serial dilution of the tissue extract was used and then the signal intensity ratio to the positive control with internal standard was recommended (Hiyama et al., 1995a,d; Wright et al., 1995) . Recently,¯uorescent based real time PCR has been developed for this quantitative analysis (Hou et al., 2001) . To avoid the false positive results by contaminating blood cells especially lymphocytes in the cell samples, we recommended the use of extracts derived from 1000 cells for one assay (Iwao et al., 1997) . The rationale for this recommendation is that extracts from 1000 adult lymphocytes do not show detectable telomerase activity (Hiyama et al., 1995c) .
Regulation of telomerase activity correlates with the expression of two major components: human telomerase RNA (hTR) (Feng et al., 1995) and human telomerase reverse transcriptase (hTERT) (Nakamura et al., 1997). Thus, detections of both hTR expression by Northern blot analysis and hTERT mRNA expression by RT ± PCR analysis are also useful for evaluation. Moreover, hTR in situ hybridization or hTERT immunohistochemistry are also applicable for evaluation as surrogate markers of telomerase expression at the cellular level and in archival paran embedded specimens (Hiyama et al., 2001) . The advantages and disadvantages of targeting hTR and hTERT expressions in cancer diagnosis are summarized in Table 1 . Several investigators showed that high hTR expression signi®cantly correlated with poor outcome on patients with cancers (Reynolds et al., 1997) . However, we should caution that low levels of hTR are expressed in cells without telomerase activity (Koyanagi et al., 2000b) . In addition, hTERT mRNA shows several splicing variants by RT ± PCR methods and some of these variants are expressed in cells that do not have telomerase activity (Ulaner et al., 1998) . Thus, for RT ± PCR analysis of hTERT mRNA expression, the primers should be designed to distinguish the active from the inactive splicing variants.
Even though hTERT protein is of very low abundance, immunohistochemistry can detect hTERT protein at the cellular level in paran-embedded tissues. In specimens of adult cancers, the signal intensity in each hTERT positive cell did not dier substantially between tumors with high and low telomerase activity. The levels of telomerase activity in tumor tissues mainly depended on the ratio of telomerase positive to telomerase negative tumor cells (Hiyama et al., 2001) . For cell or core biopsy samples, hTERT is detectable in paran-embedded section ( Figure 1 ) indicating that hTERT detection is a promising marker for cancer detection.
Telomerase as a diagnostic marker
Clinically, one indisputable trend involves the search for less invasive and more cost-eective methods for cancer diagnosis. There has been increasing use of .
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Clinical utility of telomerase in cancer E Hiyama and K Hiyama sedimented cells obtained from¯uid, secretion, washes, brushings, blood, ®ne needle aspirates, and core biopsy in diagnosis of various cancers (Table 2) . Although morphological examination remains the gold-standard for cancer diagnosis at the present time, false-negative cytology can result from inadequate preparation of the specimen. In addition, unskilled evaluation and dierences in opinions when using morphological criteria for tumor grading can be the cause of inaccurate diagnosis. Thus, there is a growing requirement for molecular markers in cancer diagnosis that are less subjected to evaluation bias. The following sections will describe the main telomerase methods currently being evaluated for utility in cancer diagnosis.
Fine needle aspiration (FNA)
Fine needle aspiration (FNA) has become a wellestablished diagnostic tool for some kinds of cancers, especially breast and thyroid cancers, because of its well-documented accuracy in diagnosis, cost eectiveness, and minimal risk. Several investigators suggested the diagnostic potential of telomerase activity in breast FNA samples for cancer (Hiyama et al., 1996a; Mokbel et al., 1999; Poremba et al., 1999a) (Table 2 ). However, all these studies were retrospective and utilized too small sample sizes to evaluate the sensitivity, speci®city, and accuracy of telomerase activity in FNA samples. In our ongoing prospective study using more than 600 patients with breast tumors, the diagnostic accuracy of telomerase activity in FNA samples was signi®cantly higher than that of cytology (86 vs 70%, P50.001) . Detection of telomerase activity in FNA samples may become useful as a diagnostic marker for breast cancer, especially for the samples that are cytologically undetermined to be malignant, and as an alert for false-negative results of FNA cytology. Interestingly, in our series, 14 cases who showed cytologically benign lesions with detectable telomerase activity did not undergo surgery or open biopsy for histological diagnosis. Among them two were subsequently diagnosed as having breast cancer later. In these cases, detectable telomerase activity might have indicated the existence of hidden cancer or the premalignant lesions of breast cancer. Nipple discharge (ductal lavage) may also become a useful and less invasive material for cancer cell detection (Leris et al., 2000) . In thyroid tumors, for which FNA is a usual diagnostic tool, benign tumors such as follicular adenoma, Graves disease, and Hashimoto disease also show telomerase activity (Matthews et al., 2001) . Although the speci®city of telomerase activity for thyroid cancer is low, it may be useful for cancer diagnosis with the combination of cytology. In liver (Nakashio et al., 1997) and pancreas (Pearson et al., 2000) , hTERT detection in FNA was reported to be useful for cancer diagnosis but the sample sizes of these studies were too small and further evaluation is required.
Secretion, washing, or brushing samples
In sedimented cells obtained from secretion, washing, or brushing samples, the positive ratios of telomerase detection varies (Table 2) . In bronchial washing cell samples including bronchio-alveolar lavage (BAL) samples, the sensitivity of telomerase is as high as 80% of that in primary cancer tissues resected (Hiyama et al., 1998; Sen et al., 2001; Yahata et al., 1998) . The false positive samples with telomerase activity were mostly derived from activated lymphocytes in the patients with in¯ammatory pulmonary diseases (Hiyama et al., 1998). Thus, as long as the pathologist is aware of lymphocytes as sources of false positive results, telomerase activity in bronchial washing cell samples may be a useful marker for early detection of cancer.
Pancreatic cancer, which is usually diagnosed by ultrasonography, computed tomography, endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP) and/or cytology, is sometimes dicult to distinguish from benign tumors using these conventional diagnostic tools. Mutations in the K-ras gene are not a speci®c marker for pancreatic cancer, because these are also detected in some patients with chronic pancreatitis (Brentnall et al., 1995) . The sensitivity (81.4%) and speci®city (94.4%) of telomerase activity in pancreatic duct cells obtained by pancreatic duct brushings or secreted juices for cancer diagnosis have been highly encouraging (Iwao et al., 1997; Morales et al., 1998; Suehara et al., 1997) . Among our telomerase positive 32 pancreatic duct cell samples obtained from patients who subsequently were determined to have pancreatic ductal cancers, four were derived from carcinoma in situ. Thus, telomerase activity may also be a useful marker for diagnosis of the hidden cancer in the pancreatic duct (Hiyama et al., 1997b; Iwao et al., 1997) . Intraductal papillarymucinous tumor (IPMT) of the pancreas is known as a tumor type that is dicult to distinguish between adenoma and carcinoma by conventional diagnostic Washing cell samples from surgically resected colon tissue . There is no data in vivo. Abbreviations: BAL, bronchio-alveolar lavage; FNA, ®ne needle aspirates Clinical utility of telomerase in cancer E Hiyama and K Hiyama tools. In IPMT, telomerase activity was also reported as a useful marker for diagnosing carcinoma (Inoue et al., 2001) . The reports of urine samples have been somewhat controversial in regards to telomerase detection (Orlando et al., 2001) . The sensitivities in washing samples of bladder were relatively high in the patients with consequently having bladder cancer, but in the studies conducted to the present using cells obtained from voided urine the sensitivities have been variable (Heine et al., 1998; Kinoshita et al., 1997; Muller et al., 1996) . This dierence may be derived from the varying numbers of viable cells in the samples. In the samples such as sputum, bile, or cervical scrapings of the uterus, the positive ratios were extremely low in comparison to the positive ratios in tissue samples. This could be due to the presence of TRAP assay inhibitors in these specimens .
Biopsy samples
There are several reports for detecting telomerase activity in biopsy samples (Table 2 ). In skin, oral, and uterus, where biopsy samples are easily obtained, the positive ratios of detectable activity were equivalent to those of surgically resected tissues. However, some normal tissues and precancerous lesions in these organs also showed detectable telomerase activity, which caused false positive results (Parris et al., 1999; Reddy et al., 2001; Taylor et al., 1996) . In the digestive tracts, biopsy under endoscopic examination is now routine and the positive ratios of detectable telomerase activity in biopsy samples were high (Fang et al., 1999; Koyanagi et al., 2000a; Tang et al., 1998) .
Normal mucosal crypt cells in the gastrointestinal tract and the basal cells in esophagus have telomerase activity so that detection of telomerase activity in these specimens does not necessarily mean the existence of cancer cells (Hiyama et al., 1996b) . Moreover, precancerous lesions in these organs also have telomerase activity (42.3 ± 68.9%) resulting in a high incidence of false positive for cancer diagnosis (Fang et al., 1999; Koyanagi et al., 2000a; Parris et al., 1999; Rahat et al., 1999; Reddy et al., 2001; Tang et al., 1998; Zheng et al., 2000) .
Telomerase as a prognostic indicator
Several studies demonstrated that telomerase expression in cancer tissues correlated with clinical outcomes in several cancers (Table 3 ). Since telomerase activity levels appear to be higher with increased stage of cancer progression in most adenocarcinomas derived from stomach and colon (Chadeneau et al., 1995; Hiyama et al., 1995b; Tahara et al., 1995; Tatsumoto et al., 2000) , the presence of telomerase activity has been shown to correlate with poor prognosis of the patients with gastric cancer (Hiyama et al., 1995b ). In addition, the level of telomerase activity is an independent prognosis-predicting factor of colorectal cancers (Tatsumoto et al., 2000) . In stage I non-small cell lung cancers, the levels of telomerase activity correlated with the prognosis of the patients (Marchetti et al., 1999) . In a retrospective study of a large number of breast cancers, the levels of telomerase activity signi®cantly correlated with clinical outcomes and several prognostic indicators (Clark et al., 1997) . ) Adult T-cell leukema Acute myelogenous leukemia Childhood tumor Neuroblastoma (Hiyama et al., 1995a (Hiyama et al., , 1997a Poremba et al., 1999b; Reynolds et al., 1996) Wilms tumor Oncogene Clinical utility of telomerase in cancer E Hiyama and K Hiyama
Telomerase activity is a useful indicator to determine malignant grade in the group of tumors in which benign and malignant tumors are sometimes indistinguishable by morphological examination such as brain tumors (Falchetti et al., 1999; Langford et al., 1997) , papillary adenocarcinoma in thyroid (Matthews et al., 2001) , pancreatic endocrine tumors (Pearson et al., 2000) , urothelial cell carcinoma (Lancelin et al., 2000) , and cervical intraepithelial neoplasia (Wisman et al., 2001) . In these tumors, the levels of telomerase activity subsequently correlated to the prognosis of the patients.
In neuroblastoma, one of the most common tumors in childhood, high telomerase activity correlated with poor outcome, while the tumors with low activity of this enzyme showed favorable outcome (Hiyama et al., 1995a (Hiyama et al., , 1997a Poremba et al., 1999b; Streutker et al., 2001) . Typically, some stage-IVS neuroblastomas that subsequently regressed did not exhibit telomerase activity and showed shortened telomeres (Hiyama et al., 1995a (Hiyama et al., , 1997a . These results demonstrated that telomerase activity can be a useful marker for predicting outcome of the disease and for determining appropriate treatment for the patients with such tumors.
In conclusion, telomerase activity measurements have two clinical utilities for cancer diagnosis: the ®rst one is early detection of cancer cells for diagnosis of malignant tumors whose telomerase activity is upregulated in early stages, and the second is as a prognostic indicator in tumors whose telomerase is activated according to tumor progression. Immunohistochemical detection of hTERT is useful to detect telomerase positive cells in a background of noncancerous cells, and further studies may reveal important implications for telomerase as a marker for cancer diagnostics and indicators of prognosis and residual disease.
